Abstract | Antiphospholipid syndrome (APS) is an autoimmune disease defined by the presence of arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive for antiphospholipid antibodies (aPLs). APS can be isolated (known as primary APS) or associated with other autoimmune diseases, such as systemic lupus erythematosus (SLE; known as secondary APS). The kidney is a major target organ in APS and renal thrombosis can occur at any level within the vasculature of the kidney (renal arteries, intrarenal arteries, glomerular capillaries and renal veins); events reflect the site and size of the involved vessels. Histological findings vary widely, including ischaemic glomeruli and thrombotic lesions without glomerular or arterial immune deposits on immunofluorescence. Renal prognosis is affected by the presence of aPLs in patients with lupus nephritis and can be poor. In patients with SLE and aPLs, biopsy should be performed because inflammatory and thrombotic lesions require different therapeutic approaches. Renal involvement in patients with definite APS is treated by anticoagulation with long-term warfarin. The range of renal manifestations associated with APS is broadening and, therefore, aPLs have increasing relevance in end-stage renal disease, transplantation and pregnancy.
Introduction
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent arterial or venous thrombosis and/or pregnancy-related problems and persistently elevated levels of antiphospholipid antibodies (aPLs). Since the first detailed description of APS by Graham Hughes in 1983, 1 this condition has become regarded as a crossroad of coagulation and the immune system. aPLs comprise a heterogeneous group of anti bodies directed against anionic phospholipids or protein-phospholipid complexes. Laboratory tests to identify aPLs include solid-phase ELISA to detect antibodies against cardiolipin and β2-glycoprotein 1 (B2GPI) and functional assays, such as the lupus anticoagulant assay, that demonstrate the ability of aPLs to prolong phospholipid-dependent clotting reactions. Cardiolipin is an anionic phospholipid; historically it was important as an antigen in the Venereal Disease Research Laboratory (VDRL) serological test for syphilis. Blood screening for this disease led to the observation that many patients with systemic lupus erythematosus (SLE) had a positive VDRL test, without any other clinical or serological evidence of syphilis but with a tendency to form clots or morbidity in pregnancy. 1 In 1990, two indepen dent research groups showed that the true antigenic determinant of anti cardiolipin binding (that is, of autoantibodies against cardiolipin) is a phospholipidbinding protein (namely, B2GPI), rather than cardiolipin. 2 The observation that many antibodies against cardiolipin are directed to an epitope on B2GPI led to the development of the anti-B2GPI antibody immunoassay. An international consensus statement on definitive classification criteria for APS was published in 1998, 3 after a workshop in Sapporo, Japan, and was updated in 2006. 4 At least one clinical manifestation, such as vascular thrombosis or pregnancy morbidity, together with one positive laboratory test confirmed at least 12 weeks apart, are currently required for diagnosis. APS alone is usually classified as primary APS, but in the presence of other autoimmune disorders-especially SLE-the condition is generally classified as secondary APS (Figure 1 ).
Evidence suggests that the prevalence of aPLs in the general population is low. 5, 6 Standard techniques detect aPLs in <1% of apparently healthy individuals and in up to 3% of the population of people aged >65 years old who do not have clinical manifestations of APS. 4 However, the prevalence of aPLs is notably high in patients with thrombotic manifestations, such as in individuals who had their a first stroke at <50 years of age (10-26%) and in women who have had recurrent miscarriages (10-40%). 7 Among patients with SLE, 30-40% are positive for aPLs. 6, 7 Of patients with both SLE and aPLs, around half develop APS within 10-20 years. 6 Thrombotic events in patients with APS are most frequently observed in the deep veins of the lower limbs and the cerebral arterial circulation, 8 but the kidney is also a major target organ (Box 1). Thrombosis can occur at any level within the vasculature of the kidney and the manifestations of thrombotic events reflect the sites and dimensions of involved vessels. aPL-related nephropathy, therefore, warrants inclusion in the diagnosis of APS. 9 In this Review, we describe the role of aPLs in inducing renal disease and the clinical and histological features of APS that involve the kidney. We also discuss the management of patients with renal involvement, including available and upcoming therapies.
aPLs and thrombosis
In patients with circulating aPLs, thrombotic events might but do not always occur, which suggests that the presence of aPLs is necessary but not sufficient for thrombus formation in vivo. 10 Rather, aPLs purportedly create a prothrombotic state that increases the risk of thrombotic events in the presence of another pro thrombotic factor. 9 The aPL-related prothrombotic state could be induced by many different mechanisms, such as cellular effects (on platelet membranes, endothelial cells and monocytes), increases in the expression of plasma coagulation regulatory proteins (clotting components, such as antithrombin, protein C and protein S) and fibrinolysis. 11 The proposed mechanisms underlying thrombus formation can be categorized into two types. Firstly, aPLs might act in vivo by disrupting procoagulant and anticoagulant reactions on cell membranes. Secondly, aPLs might interact with specific cell-surface receptors (proteins, lipids or both) and induce signals downstream that will ultimately result in upregulation of cell-surface proteins. 11 Our research group and others have suggested that expression of tissue factor, the major coagulation initiator in vivo, by endothelial cells and monocytes is a leading mechanism contributing to thrombosis in APS. 12 Several other processes have been related to aPL-induced thrombosis, such as conformational and reductive or oxidative (also known as redox) post-translational modifications of B2GPI, decreased activity of endothelial nitric oxide synthase and complement activation. aPLs can also have direct or indirect cellular effects on endothelial cells, monocytes and platelets, mainly through binding to B2GPI expressed on cell membranes. 11 Additionally, interaction of aPLs with proteins implicated in clotting regulation-such as prothrombin, factor X, protein C and plasmin-might interfere with the inactivation of pro coagulant factors and fibrinolysis. Interactions such as these induce a prothrombotic and proinflammatory phenotype ( Figure 2 ).Traditional cardiovascular risk factors, which are present in >50% of patients with APS, 8 also frequently play an important part in thrombosis. For example, we have reported that arterial hyper tension and hyperlipidaemia are independent risk factors for thrombotic events in patients with aPLs. 13 
Clinical manifestations
Any organ can be affected in patients with APS and, therefore, the range of clinical features is extremely wide. Vessels of all sizes can be affected by thrombus formation. The appearance of vascular pathology is bland occlusion without inflammatory infiltrates in the wall of the vessels. 14 A wide spectrum of thrombotic events in the kidney have been described in association with aPLs, such as renal artery stenosis, renal infarction, renal vein thrombosis and thrombotic microangiopathy (TMA). 15, 16 Apart from TMA, various intrarenal vascular lesions have been described in primary APS, 17 including APS nephropathy (also called aPL-associated nephropathy). 18, 19 The variety in clinical manifestations is reflected in the range of histo logical findings, and includes ischaemic glomeruli and thrombotic lesions without glomerular or arterial immune deposits on immunofluorescence. 20 APS nephropathy APS nephropathy is clinically characterized by a syndrome of vascular nephropathy associated with hypertension, acute or chronic renal insufficiency, proteinuria and inconstant haematuria that can present differently depending on the rapidity of onset. Acute presentation includes TMA, whereas the chronic course favours histo pathologically characterized arterial fibrous intimal hyperplasia, tubular thyroid-like appearance, arteriosclerosis, arteriolar occlusions and focal cortical atrophy. 21 Peculiar patterns of microscopic and ultrastructural findings are usually associated with TMA 22 and manifest clinically as proteinuria, hypertension and renal impairment. 15 Proteinuria is generally mild (in the range of 0.5-3.0 g per day), but might be in the nephrotic range (>3.5 g per day). [17] [18] [19] Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome, along with other disorders that include TMA, should be ruled out, 22 although differential diagnosis can be a challenge because some clinical findings are not specific for APS nephropathy. Severe thrombocytopenia and microangiopathic anaemia are more commonly observed in thrombocytopenic purpura and haemolytic uraemic syndrome than in APS, 16 whereas the presence of schisto cytes on blood smear is rarely observed in APS. A negative aPL test is also a valid tool to distinguish between APS and other possible causes of TMA. 21 Catastrophic APS is a very severe variant of classic APS, characterized by clinical evidence of multiple organ involvement developing over a very short period of time (usually in <1 week), and histopathological evidence of multiple small vessel occlusions. Catastrophic APS should be ruled out, especially in patients who have multiple thrombosis in at least three organs, systems and/or tissues. 23 Histological findings in APS neuropathy include distinctive microangiopathic features (focal and diffuse) that might affect any of the vessels within the intra renal vasculature, including the glomeruli (Figure 3) . 1, 16, 17 In studies of kidney biopsy samples from patients with primary APS, researchers 19 showed that all vaso-occlusive lesions were characterized by acute thrombosis (TMA) and chronic vascular lesions, such as fibrous intimal hyper plasia of interlobular arteries, recanalizing thrombi in arteries and arterioles, fibrous occlusions and focal cortical atrophy. 19 Ultrastructural findings might include glomerular basement membrane reduplication associated with glomerular basement membrane wrink ling. 16 , 17 Fakhouri and co-workers 24 found evidence of glomerulonephritis in 29 biopsy samples obtained from patients with primary APS. 24 Characteristic features of APS nephropathy were observed in 20 (69%) specimens. Nevertheless, about one-third of patients had some pathological changes other than vascular APS nephro pathy, such as minimal change disease, focal segmental glomerulosclerosis, membranous glomerulonephritis, mesangial C3 nephropathy and pauci-immune crescentic glomerulonephritis. 24 In seven patients, the onset of the renal involvement was chronic or subacute. 24 Sinico and co-workers 25 retrospectively studied 160 patients with primary APS and renal involvement was present in 14 (9%). Renal biopsy samples were available for 10 patients. Histopathological changes included membranous glomerulonephritis in four of the patients, proliferative glomerulonephritis in two, TMA in two and vascular involvement as observed in chronic APS nephropathy in the remaining two patients. Membranous glomerulonephritis was characterized by immune deposits in the subepithelial area, mesangium and subendothelial space; C1q deposits, immuno globulins and C3 were also present. Two out of four patients with membranous glomerulonephritis had low levels of complement and one of these two patients was also positive for antinuclear antibodies. Moreover, two patients had diffuse proliferative glomerulonephritis resembling class IV lupus nephritis. The main histological picture, therefore, was membranous glomerulonephritis, whereas only four patients had histological lesions consistent with acute or chronic APS nephropathy. The association between aPLs and membranous glomerulonephritis is unclear, as it has been reported in some studies and anecdotal case reports, [25] [26] [27] but is unconfirmed in others. 18, 28 A 2011 retrospective study of 114 patients with lupus who had undergone renal biopsy described APS nephropathy in 32% of patients with SLE, irrespective of lupus nephritis. 15 APS nephropathy was significantly associated with lupus anticoagulant and extrarenal manifestations of APS (most frequently with arterial thrombosis and fetal loss). No associ ation was found between APS nephropathy and venous thrombosis. The researchers concluded that APS nephro pathy was an independent risk factor for hypertension, elevated serum creatinine concentrations and increased interstitial fibrosis in SLE. 15 In a large cohort of patient with SLE, another group investigated prevalence, clinical associations and longterm outcomes of APS nephropathy. 18 They diagnosed APS nephropathy in 32 (40%) out of 81 patients with aPLs, compared with only three (4%) out of 70 patients without aPLs. APS nephropathy was documented indepen dently of lupus nephritis in approximately twothirds of the patients with SLE with secondary APS. APS nephropathy was associated with the presence of lupus anticoagulant, antibodies against cardiolipin or both, but not with lupus nephritis. The authors concluded that among patients with SLE, APS nephropathy occurred almost exclusively in those with aPLs. Patients with APS nephropathy developed hypertension, raised serum creatinine levels and histological progression of lesions, all of which are associated with poor renal outcomes. However, the frequency of renal insufficiency did not differ between patients with or those without APS nephropathy after 7 years of follow-up monitoring. 18 Renal artery stenosis and thrombosis APS has been suggested as a rare cause of renal artery stenosis, which has important acute (renal infarction leading to ischaemic acute renal failure) and chronic (such as slowly progressive ischaemic renal failure) clinical consequences. Renovascular disease is also observed in some patients. 21 In 1990, Ostuni and colleagues 29 reported a case of renal artery thrombosis in a patient with aPLs. This association between aPLs, arterial hypertension and Sangle et al. 32 studied magnetic resonance angiography findings from patients with APS and resistant hypertension. Of 77 patients with APS and uncontrolled hypertension, 20 (28%) had imaging features consistent with renal artery lesions-a rate notably higher than in young hypertensive controls (8%) and healthy controls (3%). The most frequently reported pattern on imaging was smooth, delineated, generally noncritical stenosis distal to the ostium of the renal artery, although in some patients features consistent with atherosclerotic changes were noted.
The most commonly observed clinical sign associated with renal artery thrombosis is new-onset, often severe, hypertension or worsening of known systemic hypertension. Pain in the renal area, haematuria or renal failure might also occur. The aetiology varies, ranging from in situ thrombosis of the renal arteries to embo lization derived from verrucous heart valve lesions. 33 The diagnostic approach might differ depending on the severity of clinical presentation, but renal ultra sonography, abdominal CT, renal angiography, renal scintigraphy and gadolinium-enhanced magnetic resonance angiography have proved useful for diagnostic and prognostic purposes. Magnetic resonance angiography and renal ultrasonography with colour Doppler sonography are comparable methods for the detection of renal artery stenosis with narrowing of the diameter of the lumen ≥60%. 34 However, renal ultrasonography with colour Doppler sonography can be favoured as a screening method. The concept of an imaging algorithm, including ultrasonography as a screening test when appropriate and abdominal CT or magnetic resonance angiography as the second step-procedure has been proposed. 35 Renal vein thrombosis Thrombosis of the renal vein has been observed in patients with different types of APS, such as aPLpositive patients with lupus nephritis and those with primary APS. 21 Renal vein thrombosis might present with protein uria, often in the nephrotic range, and this symptom can sometimes be the first clinical manifestation of the syndrome. 1, 36 A study of a large series of patients with SLE indicated that the presence of lupus anticoagulant was strongly associated with renal thrombosis. 37 Similarly, researchers showed an association between aPL and renal vein thrombosis in two patients with SLE who were positive for lupus anticoagulant and had proliferative lupus nephirits. 38 Nephrotic syndrome is rare in patients with primary APS but is more frequent in patients who have secondary APS concomitant with SLE. 39 The renal vasculature should, therefore, be assessed with Doppler imaging to rule out renal vein thrombosis in patients who are aPLpositive and develop sudden severe proteinuria or acute impairment of renal function. Other conditions associated with the development of renal vein thrombosis should also be investigated, such as pregnancy and use of oral contraception. Renal vein thrombosis can complicate renal transplantation and affect outcomes, and these patients should receive special attention due to the increased risk of vaso-occlusive events. 40 Contrastenhanced CT and magnetic resonance angiography are valid tools to confirm renal vein thrombosis.
Renal infarction
Renal infarction has been associated with APS in case reports or case series, including patients who are aPLpositive with SLE or patients with primary APS. 33 In situ thrombosis, emboli from an upstream arterial lesion or a heart valve lesion can result in thrombotic events occurring in small-diameter intraparenchymal vessels leading to renal infarction. 3, 19 Symptoms at presentation of renal infarction include pain, hypertension (often severe) and impaired renal function, and might be one of the first features of APS. Multiple, often serious, thrombotic episodes have been described in some patients, mostly localized in the renal cortex. 41, 42 The most frequently observed histological findings are ischaemic features at the level of the glomerulus, tubular atrophy and interstitial fibrosis. 21 Notably, one group reported that in five out of eight patients with APS who underwent biopsy, histological changes consistent with TMA were not observed. 43 Subclinical renal infarction might be revealed by abdominal CT carried out for other reasons 33 but this might reveal scarring from an old silent infarct. Although renal infarction is not a classic clinical manifestation of APS, aPL testing should be carried out in young people who present with this dis order to tailor treatment if necessary. 43 Patients under going withdrawal of drugs, such as hydroxychloroquine, a disease-modifying anti-rheumatic drug commonly used in SLE, are potentially susceptible to this rare complication. 44 
Arterial hypertension
Hypertension is associated with aPLs and frequently presents with coexisting livedo reticularis.
1 Arterial hypertension affects many patients with primary and secondary APS, and has been proposed as a sensitivesign of potential renal involvement. In a study of patients with primary APS, Nochy et al. 19 reported hypertension in 15 out of 16 patients (93%) and noted that, in most, the condition was the only manifestation of possible kidney involvement. This high rate of arterial hyper tension is suggested to be due to severe vascular lesions, including fibrous intimal hyperplasia (in most of the patients), arteriosclerosis, arterial and arteriolar fibrous and fibrocellular occlusions and TMA. 16, 19 An analysis of 73 patients with borderline hypertension by Frostegard and co-workers showed higher titres of antibodies against B2GP1 in patients than in age-matched controls. 45 The presence of IgG isotype anti bodies correlated with plasma levels of insulin, insulin-like growth factor binding protein-1 and calculated insulin resistance, which suggests roles in atherosclerosis and hyper tension from the early stages onwards. Another study compared 61 healthy controls matched for age and sex with 26 patients with renal artery stenosis and 25 patients with severe essential hypertension (diastolic blood pres sure >110 mmHg or taking at least three hyper tensive drugs). 46 Two of the 25 patients (8%) with severe essential hypertension had aPLs compared with none of the controls. Several patients with malignant hypertension associated with aPLs or in the context of APS have been described. [47] [48] [49] Of note, systemic hypertension has been reported as a strong risk factor for thrombosis in patients with aPLs, which suggests that careful blood pressure control is warranted in these patients. 13, 50 Taken together, the evidence suggests that hypertension is a frequent manifestation of APS, but optimal blood pressure management might be difficult to achieve. Control of arterial hypertension and anticoagulation therapy when necessary (for example, in patients with histologically proven microthrombi) is thought to prevent progression to end-stage renal disease and future thrombosis. 16 
Effects on lupus nephritis
APS can affect the prognosis and renal outcomes in patients with lupus nephritis. Pérez Velásquez and colleagues 51 reviewed a large cohort of patients with SLE (n = 600) and reported that among those with secondary APS, 56% had renal disease and, of those, 43% had typical features of APS on biopsy. Lupus anticoagulant and IgG antibodies against cardiolipin were more prevalent in these patients than in those without APS and correlated with mortality. 51 In a prospective study of 111 patients with lupus nephritis who were followed up for a mean of 14 years, 26% of the patients were positive for aPLs, which was associated with increased incidence of thrombosis and pregnancy morbidity. 27 A strong association between aPLs and poor prognosis was also observed. Even after multivariate adjustment, the aPLs remained associated with poor renal outcomes, high plasma creatinine levels at presentation and high chronicity index scores. These findings seem to support the notion that aPLs are an independent risk factor for chronic impairment of renal function in patients with SLE, but in other studies no such association has been found. 52, 53 Another group evaluated the frequency of APS nephropathy in 151 patients with SLE who had undergone renal biopsy. 18 APS nephropathy was independently related to lupus nephritis in about two-thirds of patients who had SLE and APS and in one-third of patients with SLE and aPLs but not APS. By contrast, <5% of patients with SLE but without aPLs had any histological signs of APS nephropathy. Indeed, APS nephropathy was associated with positive tests for lupus anticoagulant and antibodies against cardiolipin. 18 The same study evaluated the progression of APS nephropathy through analysis of serial kidney findings in biopsy samples and showed evolution from acute thrombotic features to chronic thrombotic disease characterized by proliferative, obstructive and fibrotic lesions. If the first biopsy sample showed findings suggestive of TMA, chronic forms were frequently observed in the second or third biopsy specimens, for example, fibrous intimal hyperplasia, arteriolar occlusions, focal cortical atrophy or sclerotic features. 18 Another study revealed two distinct sets of findings for acute and chronic disease in biopsy specimens. 54 Fibrin thrombi in interlobular arteries and involving glomerular arterioles were frequently found in samples from patients with acute renal episodes. In samples taken months or years later, chronic disease was characterized by arteries narrowed by recanalizing thrombi, ischaemic glomeruli with double contours and cellular or fibroelastic intimal proliferation.
Coexisting APS nephropathy and lupus nephritis have been associated with poor renal outcome in some studies 30, 38 but not in others. 55 In a cohort of 51 patients with SLE, the prevalence of crescents, sclerosis and glomerular necrosis was higher in patients with APS nephropathy than in those without the disease, which supports the concept that aPLs and glomerular thrombosis are associated with poor renal outcomes. 56 More patients with aPLs had hypertension and raised creatinine levels than those without aPLs, and were often associated with thrombosis (mainly arterial) during follow-up monitoring. 18 In patients with SLE and renal involvement, therefore, the ability to distinguish between patients who have lupus nephritis (immune-complex disease) and those who have impaired kidney function related to aPLs (thrombotic events) is crucial to guiding treatment. 16 Immunosuppressive therapy is useful to treat lupus nephritis, whereas in patients with APS who have APS nephropathy lesions in renal biopsy samples, additional anticoagulation therapy might be required. 57 Patients with co-existing lupus nephritis and APS who test positive for lupus anticoagulant and have histological evidence of TMA, fibrous intimal hyperplasia or both are at increased risk of bleeding after renal biopsy. 58 These observations need confirmation, but support the notion of testing for aPLs in all patients with lupus nephritis before renal biopsy is carried out.
In summary, the prompt recognition of clinical and serological findings suggestive of renal involvement in patients with APS is crucial, and treating physicians should avoid postponing renal biopsy to ensure appropriate treatment is started early. 33 
End-stage disease and transplantation
Positive tests for aPL are more frequent among patients with end-stage renal disease than in the general population.
59-61 aPLs do not seem to be related to demographic features, such as age or sex, or to dialysis factors, including the duration of dialysis or the type of membrane used. 57 Treatments or chronic viral hepatitis do not seem to influence whether or not patients with end-stage renal disease have aPLs. 59, 62, 63 The mechanisms underlying the association between aPLs and end-stage renal disease remain unclear, although several have been proposed, including dialysis membranes, 61 blood-cell activation during the haemodialysis circuit 64 and the presence of microbial agents or their products (for example, endotoxins) in the dialysate. 65 Vaidya 66 reported that 27 out of 802 (3%) patients awaiting renal transplantation had APS. In two patients, posttransplant renal thrombosis was observed within 24 h despite warfarin therapy, which supports a potential patho genic role for aPLs in end-stage renal disease. 66 Other researchers demonstrated that anti bodies against cardio lipin detected in patients under going dialysis seemed mostly to be B2GPI-independent. 67 This finding suggests that the clinical value of measuring B2GPI-independent antibodies against cardio lipin is unclear, as the precise risk of thrombosis associated with the presence of these antibodies in patients with end-stage renal disease is not known. 65, 68 Overall, however, the evidence is inconclusive with regards to pathogenic roles of aPLs and anti bodies against cardiolipin. [66] [67] [68] [69] [70] [71] [72] [73] In some studies, the presence of aPLs was associated with an increased rate of haemodialysisassociated vascular access thrombosis. [74] [75] [76] Whether or not separate screening for anti bodies against cardiolipin and lupus anticoagulant should be considered remains uncertain as it is unclear if they are equally associ ated with recurrent access thrombosis. Some studies indicate that both lupus anticoagulant and antibodies against cardiolipin increase the risk of vascular access thrombosis, 76 but this association has been confirmed only for lupus anticoagulant. 75, 77 End-stage renal disease is a rare complication of primary APS and only a few studies have investigated this relationship. 25, 44, 78 The complication is particularly rare in paediatric patients. 79 In a large retrospective study of 160 adult patients (mean age 35 years ± 12 years) with primary APS, only one developed end-stage renal disease. 25 Similarly, only one patient with end-stage renal disease was noted in a prospective study of 39 patients with primary APS. IgA antibodies against B2GPI in patients receiving haemo dialysis have been suggested as an independent risk factor for mortality. 80 The pathogenic role of the IgA isotype, however, remains unclear and studies are needed to investigate the clinical relevance of these antibodies. 81 Several studies investigating the clinical relevance of aPLs in patients who underwent renal transplantation have indicated an increased the risk of graft failure, and thrombosis at any site within the renal vasculature. [82] [83] [84] McIntyre and Wagenknecht 85 reported that among 110 transplant recipients, those with aPLs at the time of transplantation had a higher rate of renal allograft failure than those without aPLs. In patients who undergo renal transplantation, the frequency of patients who test positive for PLs seems to be increased independent of the presence of SLE. 86 32 of 56 (57%) patients who had early kidney allograft failure had aPLs, compared with 35% of matched patients with functioning grafts. 84 Biopsy samples from the aPL-positive patients with graft failure showed thrombotic features in nine and infarction in five. 84 Indeed, anticoagulation therapy does not completely abolish the risk of graft loss or thrombosis. 87 Canaud et al. 88 reviewed 1,359 kidney transplantations carried out in a single centre and found that at the time of transplantation, 37 (2%) patients had aPLs. A notably high incidence of APS nephropathy was also observed in recipients positive for lupus anticoagulant. Furthermore, the presence of lupus anticoagulant was associated with accelerated progression of chronic vascular changes within the first year after transplantation. Biopsy analy sis at 3 months and 12 months showed that progression of tubule-interstitial chronic lesions was delayed in relation to vascular lumen narrowing, which suggests a causal link between vascular damage and graft scars. 88 Other studies, however, have found no evidence of aPLs being an independent risk factor for thrombosis after kidney transplantation. Fernández-Fresnedo and colleagues 89 studied 197 kidney grafts in cadavers of patients who had functioning grafts for >1 year. 27% of these patients had aPLs before transplantation and 16% of them developed aPLs after transplantation. The presence of aPLs in the serum before transplantation was not associated with an increased risk of post-transplant thrombosis. Furthermore, the development of aPLs after transplantation was associated with acute rejection. 89 Overall, the role of aPLs in transplant recipients is still a matter of debate. However, the control of cardiovascular risk factors should be intensified if aPLs are detected to reduce the risks of morbidity and transplant failure.
Pregnancy
Careful management of pregnancy in women with SLE and aPLs is crucial from a nephrological standpoint. Pregnancy can influence SLE activity and lead to adverse effects on the kidneys in the short term and long term 90 that might accelerate evolution to end-stage renal disease. 91 Moreover, aPL-positive status is a well-documented risk factor for morbidity in pregnancy, including recurrent miscarriage, premature delivery, intrauterine growth restriction and pre-eclampsia. 4 A possible link between hypertension and post partum renal failure in women with SLE and aPLs was suggested by Kincaid-Smith and colleagues. 54 Findings in renal biopsy samples were compatible with TMA, fibrin thrombi were present in glomeruli and arterioles and were similar to those seen in thrombocytopenic purpura and haemolytic uraemic syndrome. Of note, these findings are also common in patients who present with malignant hypertension during treatment with oral contraceptives. 33 A case of postpartum bilateral renal cortical necrosis in a woman with APS and SLE has also been reported. 92 The associations between aPLs, renal involvement and pregnancy outcomes, however, remain poorly understood. A meta-analysis indicated an association between aPLs and hypertension in pregnant women, preterm delivery and recurrent miscarriages. 90 The increased frequency of hypertension in women with APS might increase the risk of pre-eclampsia, which has a welldocumented association with APS. 90 aPLs are frequently found in patients with hypertension, independent of active lupus nephritis. 90 Women with aPLs or SLE and aPLs, irrespective of the presence of lupus nephritis, should be counselled before becoming pregnant about the potential effect of these antibodies on maternal and pregnancy outcomes. The safety of medications in pregnancy and lactation should be addressed when the patient is counselled about a future pregnancy (Box 2). In brief, current recommendations include switching patients on vitamin K antagonist to full doses of anticoagulation low-molecular-weight heparin (LMWH). 93 In patients with SLE and APS, most immunosuppressive drugs are contraindicated during pregnancy and breastfeeding, with the exception of azathioprine, cyclosporin and tacrolimus. 93 Steroid use during pregnancy, although safe, has to be kept at the lowest effective dose as it has been reported to increase the risk of maternal morbidity, including hypertension, pre-eclampsia and gestational diabetes. 93 It is important to remember that both aspirin and hydroxycloroquine are compatible with pregnancy and breastfeeding. Labetalol, methyldopa and nifedipine (and less frequently hydralazine and doxazosin) are the drugs of choice to manage hypertension in pregnancy. 94 
Catastrophic APS
Catastrophic APS is a very severe variant of classic APS, and is characterized by acute multiple organ involvement, evidence of multiple small vessel occlusions on histopathology and usually a high aPL titre. Although catastrophic APS is observed in <1% of all patients with APS, the condition is generally life threatening. 23, 95 Renal involvement is a common clinical feature of catastrophic APS. 96 Ischaemia of the bowels, lungs, heart and brain are most frequent, but in rare instances adrenal, testicular, splenic, pancreatic or skin involvement have been described. TMA is characteristic of catastrophic APS and leads to symptoms owing to dysfunction of the affected organs. Precipitating factors for catastrophic APS include infections, surgical procedures, withdrawal of anticoagulant therapy and the use of oral contraceptives. 97, 98 Tektonidou et al. 99 compared the histological findings in renal biopsy samples from patients with catastrophic APS (n = 6), primary APS (n = 8) and secondary APS (with SLE; n = 23). Acute vascular lesions were documented in all patients with catastrophic APS and around one-third of patients with primary APS and secondary APS. Chronic changes were noted in two-thirds of patients in all APS groups. This study supports other observations that the main distinguishing feature of catastrophic APS is the high frequency of the acute changes.
Treatment
The treatment of patients with aPLs but without previous thrombotic events remains controversial. The current consensus is not to treat patients who have low aPL titres or who are intermittently aPL-positive. 100 In patients with persistent medium to high aPL titres, strict control of conventional risk factors for cardiovascular disease, such as hypertension, hypercholesterolemia and smoking, is essential. 101 Patients positive for multiple risk factors (lupus anticoagulant, as well as antibodies against cardiolipin and B2GPI) are at increased risk of thrombosis 13, 102, 103 and might benefit from anti-aggregation therapy. 104 All patients with aPLs should receive primary thrombo prophylaxis with low-molecular-weight heparin in prothrombotic situations, such as surgery or immobilization. Some studies suggest use of hydroxychloroquine 105, 106 and statins 103 in patients with persistently high aPL titres. Long-term treatment of APS with warfarin for arterial or venous thrombosis is recommended (Box 2). 100, 107 Treatment with intermediate-intensity warfarin (international normalized ratio of 2.0-3.0) is usually effective in patients after the first episode of venous thrombosis. Patients with arterial thrombosis or recurrent thrombotic events despite ongoing treatment might require high intensity warfarin treatment (international normalized ratio of 3.0-4.0). The use of an additional antiplatelet agent could be considered. 100, 107 Renal artery stenosis can be managed with antihypertensive agents, antiplatelet drugs or anticoagulants. 33 Our research group analysed 14 patients with hyper tension, APS and renal artery stenosis who received oral anticoagulation for >1 year. All patients benefited in terms of blood pressure and renal outcomes, 33 which confirmed the finding by Remondino and co-workers, 108 who reported the recanalization of bilateral renal artery stenosis after anticoagulation treatment in a young woman with previously documented hypertension and APS. These observations support a role for anticoagulation therapy to prevent the progression of renal artery lesions. 109 A history of renal disease related to APS (especially renal impairment) is associated with complications during pregnancy and the puerperium. For these reasons, close multidisciplinary management, including obstetricians and nephrologists, is crucial to improve pregnancy outcomes. 21 Although corticosteroids, hydroxy cloroquine 110 and some immunosuppressive agents have occasionally been reported to reduce aPL titres, 111 whether they have a role in reducing the risk of thrombosis is unproven. Some studies have assessed the role of immunosuppressant agents in primary APS nephropathy and have noted favourable effects. 112, 113 Korkmaz et al. 112 described four patients with primary APS with renal involvement who responded to steroids plus azathioprine or cyclophosphomide added to anti coagulation therapy. Corticosteroids and other immunosuppressants, however, are not generally recommended for the tr eatment of APS.
Patients with catastrophic APS are frequently treated with a combination of anticoagulants and corticosteroids plus intravenous immunoglobulin, and/or plasma exchange as first-line therapy. 21 The use of Refractory or difficult cases (difficult INR warfarin control, bleeding or major bleeding risk) ■ Alternative therapies could be explored, including long-term LMWH, hydroxychloroquine, statins or biological therapy (for example, rituximab), but data from clinical trials to prove the efficacy of these drugs to prevent recurrent thrombosis are lacking.
*Recommendations based on the study by Ruiz-Irastorza et al. 100 Abbreviations: aBGPI, antibody against β2-glycoprotein I; aCL, antibody against cardiolipin; aPL, antibody against phospholipid; APS, antiphospholipid syndrome; INR, international normalized ratio; LA, lupus anticoagulant; LMWH, low-molecular-weight heparin; SLE, systemic lupus erythematosus.
cyclophosphamide, therefore, might be useful to treat catastrophic APS in patients with co-existing SLE. 23 Long-term intravenous immunoglobulin therapy has been reported in a few patients with primary APS; however, the patients relapsed despite standard treatment. 114 New oral anticoagulants, such as dabigatran and rivaroxaban, are available and have been shown to be efficacious in the management of venous thromboembolism without requiring laboratory monitoring. 115 An efficacy and safety trial of rivaroxaban in APS is under way.
116
B-cell depletion with rituximab has been suggested for use in selected patients with APS, mainly in those with severe thrombocytopenia. 111 Erkan and co-workers 117 conducted a 12-month, phase II pilot study of rituximab therapy, to investigate adult patients with aPLs and APS manifestations not currently included in the updated classification criteria. 4 One patient was diagnosed as having nephropathy and achieved partial remission with no recurrence after two doses of 1,000 mg rituximab on day 1 and day 15. Other targeted therapies have been effica cious in experimental models of APS. 118 For example, acute recurrence of TMA after renal transplantation was successfully treated with eculizumab, an antibody against C5, which suggests that such therapy could be beneficial in patients with fulminant recurrence of TMA and resistant to classical therapy. 119 Future studies exploring the mechanisms of aPLs in inducing the clinical manifestations associated with APS will be useful in the design of further tailored approaches.
Conclusions
The kidney is a major target organ in primary and secondary APS. Renal involvement is a well-recognized manifestation of the syndrome and is characterized by thrombosis that can affect any vascular site in the kidneys. Treatment of renal involvement in patients with definite APS involves long-term anticoagulation therapy with warfarin. New oral anticoagulants have been developed for clinical use and a trial to assess the efficacy and safety of rivaroxaban in APS is ongoing. Other therapeutic approaches, including the use of intravenous immuno globulins, rituximab or eculizumab, might be useful in patients who are refractory to standard treatment. Future studies need to focus on the pathogenesis of APS, which might yield potential targets for treatment, such as tissue factor pathways and complement factor inhibitors. A need exists for clinical trials to improve outcomes in APS, solve the crucial issues that include the risk of thrombosis in patients with aPLs and develop a tailored approach to therapy in treatment-resistant patients.
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